Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis
Published: 18 November 2020 Click HERE to Subscribe for the MS Beacon Newsletter Abstract Spinal cord involvement is a hallmark…
New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Click HERE to Subscribe for the MS Beacon Newsletter ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III…
Stuart Schlossman
CoViMS Registry for those with MS, and other CNS demyelinating diseases (Neuromyelitis Optica Spectrum Disease, or MOG antibody disease) who have developed COVID-19
*** This COViMS (COVID-19 Infections in MS & Related Diseases) is a joint effort of the National MS Society, the…
Stuart Schlossman
Satralizumab Approved for Treatment of Neuromyelitis Optica Spectrum Disorder
The subcutaneous injection is indicated in patients with anti-aquaporin-4 antibody positive NMOSD. By: Alicia Bigica – August 15, 2020…
Stuart Schlossman
While NMOSD shares a number of features with MS, a key difference is that NMOSD relapses cause symptoms and disability to accumulate, which is often irreversible
Stay Healthy, Stay Home and Wash Your Hands ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of…
Stuart Schlossman
Satralizumab Shows Safe Profile in Patients With NMOSD (NMO)
Benjamin Greeberg, MD Results from the combined double-blind and open-label extension periods of the SAkuraSky (NCT02028884) and SAkuraStar (NCT02073279) clinical…
Stuart Schlossman
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
Sunday – December 1, 2019 Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse…
Stuart Schlossman
Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Spectrum Disorder
Pivotal Phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at…
Stuart Schlossman
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
Published: Sep 04, 2019 Sept. 4, 2019 05:00 UTC Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal…
Stuart Schlossman
Devic’s Disease (Neuromyelitis)
Devic’s disease is also called neuromyelitis optica or NMO; it is a condition often confused with multiple sclerosis. The optic…
Stuart Schlossman
